Multi-center study reveals unique subtypes of most common malignant brain cancer
An international collaborative study has revealed detailed new information about diffuse glioma, the most common type of tumor found in some 80 percent of adult brain cancer patients, raising hopes that better understanding of these disease groups may aid improved clinical outcomes.
The study, led by researchers at The University of Texas MD Anderson Cancer Center, Columbia University Medical Center, New York, and the University...
MD Anderson joins nation’s cancer centers in endorsement of HPV vaccination for cancer prevention
In response to low national vaccination rates for the human papillomavirus (HPV), The University of Texas MD Anderson Cancer Center has joined...
Targeted Axillary Dissection of lymph nodes after chemotherapy improves staging accuracy of node-positive breast cancer patients
A new procedure developed by surgeons at The University of Texas MD Anderson Cancer Center improves the accuracy of axillary staging and pathologic...
Potential therapeutic targets identified for multiple sclerosis
Treatment of multiple sclerosis (MS) and other inflammatory diseases may benefit by new findings from a study that identified potential therapeutic targets for a devastating disease striking some 2.3 million people worldwide.
Inflammation is an important part of body’s response against infections and tissue damage, but unresolved inflammation contributes to the pathogenesis of a variety of diseases and promotes cancer development...
New findings may enhance PARP inhibitors therapy in breast cancer
Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced...
MD Anderson and Enumeral enter into collaborative research and development agreement
The University of Texas MD Anderson Cancer Center today announced that it has entered into a collaborative research and development agreement...
MD Anderson and Kymab announce research and development strategic partnership in immuno-oncology
Kymab, a leading human monoclonal antibody biopharmaceutical company, and The University of Texas MD Anderson Oncology Research for Biologics...
Lymphoma/Myeloma symposium for patients and caregivers set for Feb. 6
Patients with lymphoma or myeloma and their caregivers will have access to leading experts in this field of cancer during an upcoming symposium...